


Sub-hub founded in UZ/KU Leuven



INNODIA has several immune hubs (i.e., KCL, HMGU/TUD, and LUMC) and sub-hubs (I;E;, INSERM, UH, and USI) where peripheral blood samples from unaffected first degree relatives of people with type 1 diabetes and newly diagnosed people with type 1 diabetes are frozen and prepared for shipment and analysis. In 2020, four clinical trials started in children, adolescents, and adults, aged 5 until 45 years and within 6 weeks from clinical diagnosis. All trials are running on the INNODIA Master Protocol. All samples are generated and processed via this protocol, allowing comparison not only within trials but also across trials. To support the other immune hubs with their workload especially with the large number of trial samples, another sub-hub in Leuven was founded in January 2022. Here, peripheral blood samples from the IMPACT and VERA-T-1D trial, coming from all Belgian sites and possibly also from Lithuania, are processed, stored, and eventually shipped to KCL for further analysis.

The hub is coordinated by dr. Conny Gysemans (lab manager of the diabetes center of the KU Leuven). Two study nurses (Nele Vanmechelen and Eline Roelants) and two lab technicians (Marijke Viaene and Marc Packbier) are responsible for the isolation of peripheral blood mononuclear cells (PBMC). These need to be frozen and stored until further analysis.

This dedicated team is also responsible for miRNA isolation on peripheral blood taken within Master Protocol.



Moreover, all samples require registration in the INNODIA warehouse.

